This document is a confidential investment report page (marked House Oversight) detailing the track record of New Leaf Ventures (NLV) in the biopharmaceutical sector. It highlights their investment strategy, networking capabilities, and specific performance metrics (multiples on invested capital) for various portfolio companies across funds NLV-I, NLV-II, and Sprout Funds. The text lists specific exits and IPOs occurring between 2011 and 2013.
This document is a page from a corporate prospectus or due diligence report (marked Confidential, House Oversight) detailing the professional biographies of three Managing Directors at New Leaf (presumably New Leaf Venture Partners): Jeani Delagardelle, Ron Hunt, and Vijay Lathi. All three were previously associated with Sprout Group. The document lists their educational backgrounds and extensive board memberships across various pharmaceutical and medical technology companies.
This document is a confidential financial schedule for 'Sprout Capital IX, L.P. (Healthcare Technology Portfolio)' as of March 31, 2014. It details realized and unrealized investments in numerous healthcare and biotechnology companies, listing vintage years, costs, realized values, and IRRs. The document bears a 'HOUSE_OVERSIGHT' footer, indicating it was part of a congressional investigation.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity